resolvin


Also found in: Wikipedia.

resolvin

(ri-sol′vĭn)
An anti-inflammatory lipid derived from eicosapentanoic acid (an omega-3-fatty acid).
References in periodicals archive ?
Resolvin D1 stimulates alveolar fluid clearance through alveolar epithelial sodium channel, Na, K-ATPase via ALX/cAMP/PI3K pathway in lipopolysaccharide-induced acute lung injury.
The inaugural winner is "Resolvin El Reverses Experimental Periodontitis and Dysbiosis," which was published in October 2016 in the Journal of Immunology.
Aliberti et al., "Stereochemical assignment, antiinflammatory properties, and receptor for the omega3 lipid mediator resolvin E1," The Journal of Experimental Medicine, vol.
Sun, "Resolvin D1 inhibits mechanical hypersensitivity in sciatica by modulating the expression of nuclear factor-Th, phospho-extracellular signal-regulated kinase, and pro- and antiinflammatory cytokines in the spinal cord and dorsal root ganglion," Anesthesiology, vol.
Barbosa, "Development of an immunomodulatory biomaterial: using resolvin d1 to modulate inflammation," Biomaterials, vol.
Previously, we have demonstrated that increasing the dietary content of fish oil alone or in combination is an effective treatment for vascular and neural complications in diabetic rodents [3, 4].We have also shown that cotreatment of type 1 diabetic mice with menhaden (fish) oil and salsalate is more effective toward neuropathy than menhaden oil alone and that circulating resolvin D1 levels are increased when salsalate is combined with menhaden oil [5].
Previous studies have shown that salivary levels of inflammatory markers, e.g., CRP, matrix metalloproteinase (MMP)-9 [1], and the resolvin to leukotriene ratio [4], are significantly associated with cIMT.
Spite, "Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice," The FASEB Journal, vol.
Serhan, "Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation," Journal of Immunology, vol.
s[PLA.sub.2]-IID is an "immunosuppressive s[PLA.sub.2]" that attenuates DC-mediated adaptive immunity by hydrolyzing PE probably in microparticles to mobilize anti-inflammatory [omega]3 PUFAs and their metabolites such as resolvin D1 (RvD1).
Resolvin D1, Resolvin D2, and 17-HDoHE were not detected above the LOD in any of the samples, so we excluded these metabolites from further statistical analysis.
In 2010, an endogenous mediator called resolvin E1 was presented for the first candidate as a novel therapeutic for acute lung injury and pneumonia due to E.